8dragon Those who has follow NG for the past 10 years will know this is a con co, talk big but nvr materialized....
--------------
Those who studied the company past record would realized that.

I'm eager to see its incoming 3QR 2021. Its necessary for me to be more confirmed about it.

The Edge (26 June 2021):
(MYEG) is ready to supply an initial 10 million doses of Covid-19 vaccines as soon as the Government opens up private market vaccinations, the group said after inking a letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd (Zhifei) for the vaccines.
MYEG said the letter of intent was signed pursuant to its receipt of a letter of no objection from the government for the group to purchase Zhifei’s vaccine.

www.bursamalaysia.com (23 November 2020):
"The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia."

NOTE:
1. The Zhifei Longcom, China Covid-19 vaccine is still in their preliminary stage of approval process with WHO. I think only the vaccines with the WHO approval will be given approval by NPRA to be imported to Malaysia. Instead, the Sinopharm Covid-19 vaccine already approved by WHO.

2. Kanger’s proposal to purchase Covid-19 vaccines for private use in Malaysia already given the the letter of no objection from NIBM, an agency under MOSTI much earlier in November 2020.

The Edge (26 June 2021):
(MYEG) is ready to supply an initial 10 million doses of Covid-19 vaccines as soon as the Government opens up private market vaccinations, the group said after inking a letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd (Zhifei) for the vaccines.
MYEG said the letter of intent was signed pursuant to its receipt of a letter of no objection from the government for the group to purchase Zhifei’s vaccine.

www.bursamalaysia.com (23 November 2020):
"The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia."

NOTE:
1. The Zhifei Longcom, China Covid-19 vaccine is still in their preliminary stage of approval process with WHO. I think only the vaccines with the WHO approval will be given approval by NPRA to be imported to Malaysia. Instead, the Sinopharm Covid-19 vaccine already approved by WHO.

2. Kanger’s proposal to purchase Covid-19 vaccines for private use in Malaysia already given the the letter of no objection from NIBM, an agency under MOSTI much earlier in November 2020.

The Edge (26 June 2021):
(MYEG) is ready to supply an initial 10 million doses of Covid-19 vaccines as soon as the Government opens up private market vaccinations, the group said after inking a letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd (Zhifei) for the vaccines.
MYEG said the letter of intent was signed pursuant to its receipt of a letter of no objection from the government for the group to purchase Zhifei’s vaccine.

www.bursamalaysia.com (23 November 2020):
"The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia."

NOTE:

1. The Zhifei Longcom, China Covid-19 vaccine is still in their preliminary stage of approval process with WHO. I think only the vaccines with the WHO approval will be given approval by NPRA to be imported to Malaysia. Instead, the Sinopharm Covid-19 vaccine already approved by WHO.

2. Kanger’s proposal to purchase Covid-19 vaccines for private use in Malaysia already given the the letter of no objection from NIBM, an agency under MOSTI much earlier in November 2020.

@8dragon. Nice to see you again, dear sister.

@DRwarrant. Bravo Bro.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

“However, NPRA also said that it would SIMPLY the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

NOTE: The Zhifei Longcom, China Covid-19 vaccine is their preliminary stage of approval process with WHO. I think only the vaccines with the WHO approval will be given approval by NPRA to be imported to Malaysia.

civicfc Nexgram Qr report jun or July..
-------------
Kalau ikut jadual sebenar dan tiada kebenaran untuk ditangguhkan, ianya perlu dilaporkan akhir Jun.

Also can see (two articles with the same content):

1. https://www.malaysiastock.biz/Blog/BlogArticle.aspx?tid=24568

2. https://klse.i3investor.com/blogs/mzm511/2021-06-11-story-h1566077052-A_Pre_3QR_2021_Reporting_A_Glance_at_the_Revenue_and_Profit_Growth_of_N.jsp

KUALA LUMPUR: Pharmaniaga Bhd (Pharmaniaga) has taken up a financing facility from Standard Chartered Malaysia Bhd for the import and distribution of Sinovac Covid-19 vaccines to the public and private sectors.

https://www.nst.com.my/business/2021/06/701495/pharmaniaga-takes-financing-facility-stanchart-import-distribution-covid-19

He pointed out that it is expected that in August, some PRIVATE COMPANIES will be approved to introduce the new crown vaccine from China. For example, Sinopharm vaccine can also be registered in Malaysia by then.

Source: https://www.orientaldaily.com.my/news/nation/2021/06/24/420158
-----------------

"some PRIVATE COMPANIES " ??? (Its for a number of Covid-19 vaccines from China aimed to be distributed for private market. Pharmaniaga has been given the nod to import more Sinovac vaccine for private market).

Is this reffered to GLC only???

What is good for Kanger is, the company has already signed a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia. Under the agreement, Sinopharm Group has appointed KIB as the DISTRIBUTOR for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia.

KUALA LUMPUR: Pharmaniaga Bhd (Pharmaniaga) has taken up a financing facility from Standard Chartered Malaysia Bhd for the import and distribution of Sinovac Covid-19 vaccines to the public and private sectors.

https://www.nst.com.my/business/2021/06/701495/pharmaniaga-takes-financing-facility-stanchart-import-distribution-covid-19

He pointed out that it is expected that in August, some PRIVATE COMPANIES will be approved to introduce the new crown vaccine from China. For example, Sinopharm vaccine can also be registered in Malaysia by then.

Source: https://www.orientaldaily.com.my/news/nation/2021/06/24/420158
-----------------

some PRIVATE COMPANIES (untuk beberapa jenis vaksin dari China untuk pasaran swasta, termasuk SinoVac yang telah diberi kebenaran kepada Pharma untuk diimport bagi kegunaan pasaran swasta) ---- Termasuk GLC juga ka ni?

Apa yang baik untuk Kanger ialah, Kanger telah ada tandatangani distributorship agreement dengan pihak Sinopharm (anak syarikatnya iaitu Sinopharm Group Hunan Changde....)

JK22 GLC company lagi.. So which GLC market now talking to China.
------------------
Ada plan lain, Pharma beli China vaccine seperti Sinovac untuk edaran kepada swasta.

Dan untuk Sinopharm, boleh lihat di bawah ini


Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.

Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

JUST A RESULT OF AN OBSERVATION TO SHARE:

1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.
The report was made on 9 March 2021 said that Kanger International Bhd will
receive 10,000 doses of a Covid-19 vaccine for trial purposes in May 2021.

2. The Sinopharm Covid-19 vaccine completed its 3rd Trial and approved by
WHO on 7 May 2021.

3. Therefore, if Kanger want to bring the vaccine in May to Malaysia for trial purposes,
the plan is not valid anymore because the vaccine has been finished its 3rd Trial.

4. The first plan to bring vaccine for trial purposes terminated, and the plan would be revised to,
registering the vaccine with NPRA as it is the WHO approved vaccine.

5. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

6. There will be a big probability that the report by Kanger official is true,that the company has
started to register the said vaccine with NPRA, based on 27 May 2021 report.

Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know Sinopharm and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know Sinopharm and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

1. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

As per report on 21 May 2021: "The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA)", says Khairy Jamaluddin.

2. The earliest registering date with NPRA can posibly be done after 21 May 2021.

3. Reports by Kanger official on 27 May 2021 stated that Kanger has started the process of registering the Sinopharm vaccine with NPRA.

As per report: “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

1. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

As per report on 21 May 2021: "The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA)", says Khairy Jamaluddin.

2. The earliest registering date with NPRA can posibly be done after 21 May 2021.

3. Reports by Kanger official on 27 May 2021 stated that Kanger has started the process of registering the Sinopharm vaccine with NPRA.

As per report: “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

Bukan QR lah. Financial Year 2021.

Therefore, I CONCLUDED THAT MY TARGET FOR NEXGRAM'S FY 2021 revenue WILL BE MORE THAN 100 MILIONS.*

Remember. Vaccine is still a probability.

This RI is not a bonus issue. This free warrant is just a kind of sweetener for the RI subscribers.

The RI issue is not related to vaccine distributorship proposal.

Its related to other expansion plans which is probably included:

1. The newly construction services business.
2. The proposed plan to acquire property for investment.
3. The proposed plan to acquire a company which involved in a construction material trading.

The answer is there. Just to give "my own explanation and idea" on the issue which is in concern.
Happy reading. He He

Also, the specific plan maybe faced certain changes in the conditions which caused the plan needed to be revised.
--------------

On this possibility.....

1. The report was made on 9 March 2021 said that Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine for trial purposes.

2. The Sinopharm Covid-19 vaccine completed its 3rd Trial and approved by WHO on 7 May 2021.

3. Therefore, if Kanger want to bring the vaccine in May to Malaysia for trial purposes, the plan is not valid anymore because the vaccine has been finished its 3rd Trial.

4. The first plan to bring vaccine for trial purposes terminated, and the plan would be revised to, registering the vaccine with NPRA as it is the WHO approved vaccine.

Its may be a conflict of interest involved. They maybe did it for their own sake.

Also, a specific plan may has its own requirement to be achieved before its can be done.

Also, the specific plan maybe faced certain changes in the conditions which caused the plan needed to be revised.

@satriahijau. Semua senarai produk ada sini:

https://wap.china.cn/Bamboo-Flooring/krbamboo/product.html

Thank you 2Noobie123

Noobie123 I also hope Sinopharm get approved by NPRA
----------------
Betul. Saya pun dalam situasi sama. Hanya harapan saja yang dapat dikongsi.

Untuk saya, saya terlekat dalam satu saham saya cuba ambil langkah yang saya kira positif untuk membantu kaunter tersebut supaya ada harapan untuk naik kembali. Hanya usaha, kejayaan ditentukan oleh minat pelabur-pelabur di pasaran dan juga operator, kalau ada.

Berbeza, ada sesetengah orang yang lain, bila terlekat sesuatu kaunter saham, frust dan ambil jalan kutuk kaunter tersebut. Mungkin cara tersebut juga sesuai dengan matlamat mereka, termasuk untuk turunkan harga bagi beli balik pada harga rendah untuk average down saham mereka.

Noobie123 Bingo....If Sinopharm was truly just registered with NPRA.
The big question is "IF" which means don't know, unsure, not confirmed.
----------------
Betul tu. Saya bukan insider atau agen kepada insider pun. Semua berdasarkan cerita / report yang diperoleh dari web.

Awak tengok, saya berhati-hati dalam laporan saya. Seboleh-bolehnya laporkan berita berdasarkan report sebenar.

Tak ada siapa pun saya point senapang untuk tembak untuk membaca dan percaya idea ini. Tapi adat nak share, itu saja.

Apa-apa keputusan ambil keputusan sendiri. TAYOR

@18KHarmoni.

Itu saja kah yang awak boleh cakap. Kalau nak kaunter atau menidakkan pandangan saya pun jadilah sedikit rasinal dengan pandangan bernas dan bukti yang awak boleh kemukakan.

Saya tak suka cakap kosong seperti setengah orang. Ada bukti dan pakai logik.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO.

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”
Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO,

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO,

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

No report about it. The time schedule is lapsed.
But for me I stressed on their relation with Sinopharm and their ability to be an elected distributor for the vaccine in Malaysia.

By the way, the Sinophar vaccine has been finished their 3rd Trial, and already approved by WHO.

MrWinMoney PN19 in-coming? Saw it everywhere.
----------------------
PN-19? What is it, bro? Is it a tittle for a ghost movie?

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

I want to give my views on whistlebower99's post about the RI.

Ingatkan cerdik punya naysayer. Rupanya sama seperti nama diberi. He He

@olangbolo.
--------------------
Dibawah inikan yang saya cakap. Bukan only comment after RI.

Saya berhenti setakat ini dahulu, sehimgga ada berita baru.
Teruskanlah cerita hantu awak tu. He He
18/06/2021 3:27 PM

olangbolo ada lagi plomoter bolo ni
---------------
Okaylah. Saya promoter bodoh. Minta awak pula lah cadangkan analisis awak.
Semua orang sedang tunggu analisis awak yang cerdik.
Sekadar nak cakap Kanger tipu,orang gi la belakang rumah saya pun boleh buat analisis.

Beri sebablah, apa yang tipu tu. Biar semua orang boleh kaji betul atau tidak.

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

@zzzzzzz. Oleh sebab sejarahnya tak baiklah, company punya share pernah turun sampai harga terendah. Sekarang saja ia nampak ada naik balik walaupun sedikit, itu pun setelah company terlibat dengan Healthcare berkaitan dengan Covid-19.

Saya post balik Soal Jawab dengan BOD semasa AGM 2020 yang lalu.
Bukan nak ulang berita tetap boleh dijadikan panduan untuk kita sama-sama lihat balik arah tujuan BOD untuk FY2021.

---------
From QA at AGM 2020:
The company expected to turn profitable earliest in the FY2021.

1. The medical division will potentially contribute to the company growth in near future. A little explanation about the vaccine JV.
2. The Cyberjaya project has been terminated (should be Angkasa Project) caused the big loss in the last QRs (caused by write-off of the land held for property development).
3. The co also has a plan to use the land for medical center to coop with the medical business expansion.
4. Expected revenues from medical (RM10 mil) and construction (RM28 mil) for FY Ended 31 July 2021.
5. The big losses in 4th QR 2020 is from one-off items. Not to be incurred in the next QR reports.
6. The co is positively believes that the medical and construction will be able to contribute for a better net operating cash flow.
7. On the risk to be GN3 listing issuer. The risk is smaller because medical and construction businesses will help the co to increase the shareholders equity and eliminates the possibility of the co to be listed as GN3 listing co.

@zzzzzzz. Tak tahulah saya. Itu pandangan awak.
Yang saya yakin, masalah prestasi kewangan dari segi revenue dan kemungkinan mendapat untung adalah tinggi quarter dan FY21 ini. Saya rasa ianya akan direlease dari dikenakan GN3.
Sekadar ikhlas dari pandangan saya saja.

Cuma, sejarah company yang lalu adalah tak baik. Itu menyebabkan pelabur susah mahu percaya.